| Target | Candidate | Indication | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Rights |
|---|---|---|---|---|---|---|---|---|
| PD-L1xVEGF |
SYN-2510 (Publications) |
Multiple Solid Tumors |
Global (ex-Greater China) |
|||||
| CTLA-4 |
SYN-27M (Publications) |
Multiple Solid Tumors |
Global (ex-Greater China) |
|||||
| FRα |
CoStAR-TIL (Publications) |
NSCLC | Global | |||||
NSCLC: non-small cell lung cancer; FRα: Folate Receptor α; PD-L1: Programmed death-ligand 1; VEGF: Vascular endothelial growth factor; Cytotoxic T-lymphocyte associated protein 4;